Drug Makers See Profit Potential In Rare Diseases by Jonathan D. Rockoff. The Wall Street Journal. January 30, 2013.
Drugs designed to treat rare diseases were once neglected as unprofitable by pharmaceutical companies. This article presents several drugs that show that this is no longer the case. Incentives from the FDA include quicker approval, tax benefits, and protection from competition make this class of products quite attractive. Also, the narrow genetic focus of these drugs also makes unnecessary, large-scale and expensive clinical trials. This drugs also often have astronomical prices--often covered by insurance-- making them a very profitable contributor to pharmaceutical companies revenue.
No comments:
Post a Comment